Skip to content
A new avenue for migraine therapy episode artwork

Jan 4, 2026 6 min

A new avenue for migraine therapy

from Paperleap podcast Hosted by Paperleap

A new study has identified the gene NEAT1 as a driver of light sensitivity (photophobia) in migraine sufferers. By silencing this gene in mice, researchers were able to reduce their light aversion, suggesting a potential new therapeutic target. The study reveals a molecular pathway involving NEAT1, miR-196a-5p, and TRPM3, opening doors for more targeted migraine treatments. Read the full article at https://www.paperleap.com/blog/articles/a-new-avenue-for-migraine-therapy-0ccc2x

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

A new avenue for migraine therapy

0:00 6:46

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Paperleap podcast?

This episode is 6 minutes long.

When was this Paperleap podcast episode published?

This episode was published on January 4, 2026.

Can I download this Paperleap podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.